| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epidermolysis Bullosa | 13 | 2024 | 29 | 2.200 |
Why?
|
| Dermatitis, Atopic | 11 | 2024 | 54 | 2.020 |
Why?
|
| Neurocutaneous Syndromes | 4 | 2024 | 16 | 1.590 |
Why?
|
| Lipomatosis | 2 | 2024 | 15 | 1.330 |
Why?
|
| Ectodermal Dysplasia | 3 | 2024 | 47 | 1.220 |
Why?
|
| Epidermolysis Bullosa Dystrophica | 5 | 2025 | 46 | 1.000 |
Why?
|
| Eye Diseases | 3 | 2024 | 108 | 0.940 |
Why?
|
| Eosinophilia | 2 | 2020 | 109 | 0.920 |
Why?
|
| Skin Abnormalities | 2 | 2024 | 35 | 0.850 |
Why?
|
| Acne Vulgaris | 6 | 2022 | 26 | 0.850 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2024 | 21 | 0.830 |
Why?
|
| Pyrimidinones | 1 | 2024 | 65 | 0.810 |
Why?
|
| Skin | 10 | 2022 | 553 | 0.810 |
Why?
|
| Hemangioma | 4 | 2025 | 92 | 0.770 |
Why?
|
| Pyridones | 1 | 2024 | 148 | 0.760 |
Why?
|
| Eye Abnormalities | 4 | 2024 | 107 | 0.760 |
Why?
|
| Ichthyosis | 3 | 2024 | 31 | 0.760 |
Why?
|
| Eczema | 2 | 2022 | 35 | 0.740 |
Why?
|
| Immunosuppressive Agents | 3 | 2024 | 667 | 0.730 |
Why?
|
| Skin Neoplasms | 5 | 2025 | 904 | 0.730 |
Why?
|
| Severity of Illness Index | 16 | 2025 | 3089 | 0.680 |
Why?
|
| Sirolimus | 2 | 2025 | 231 | 0.670 |
Why?
|
| Pemphigoid, Bullous | 1 | 2020 | 5 | 0.660 |
Why?
|
| Syringoma | 1 | 2020 | 2 | 0.660 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2020 | 15 | 0.650 |
Why?
|
| Mastocytosis | 1 | 2019 | 7 | 0.600 |
Why?
|
| Exanthema | 1 | 2020 | 74 | 0.600 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2019 | 62 | 0.590 |
Why?
|
| Skin Diseases | 5 | 2014 | 141 | 0.580 |
Why?
|
| Dermatologic Agents | 5 | 2025 | 31 | 0.580 |
Why?
|
| Molluscum Contagiosum | 2 | 2016 | 11 | 0.560 |
Why?
|
| Scalp Dermatoses | 1 | 2017 | 6 | 0.540 |
Why?
|
| Patient Care Planning | 1 | 2018 | 123 | 0.520 |
Why?
|
| Humans | 86 | 2025 | 131501 | 0.520 |
Why?
|
| Propranolol | 1 | 2017 | 111 | 0.510 |
Why?
|
| Plectin | 1 | 2016 | 6 | 0.510 |
Why?
|
| Ichthyosiform Erythroderma, Congenital | 2 | 2025 | 5 | 0.510 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2017 | 102 | 0.510 |
Why?
|
| Limb Deformities, Congenital | 1 | 2017 | 117 | 0.500 |
Why?
|
| Urologic Diseases | 1 | 2016 | 43 | 0.490 |
Why?
|
| Dermatology | 5 | 2024 | 33 | 0.490 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2017 | 215 | 0.480 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2024 | 3911 | 0.470 |
Why?
|
| Dermatitis | 2 | 2013 | 29 | 0.470 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2019 | 1005 | 0.450 |
Why?
|
| Erythema | 3 | 2024 | 29 | 0.420 |
Why?
|
| Child | 41 | 2025 | 26240 | 0.410 |
Why?
|
| Infant, Newborn | 13 | 2024 | 8589 | 0.400 |
Why?
|
| Rickets | 1 | 2013 | 7 | 0.390 |
Why?
|
| Perineum | 3 | 2014 | 49 | 0.390 |
Why?
|
| Ear Diseases | 1 | 2013 | 23 | 0.380 |
Why?
|
| Ichthyosis, Lamellar | 2 | 2024 | 7 | 0.380 |
Why?
|
| Professional-Family Relations | 1 | 2013 | 95 | 0.370 |
Why?
|
| Infant | 25 | 2025 | 13300 | 0.370 |
Why?
|
| Parvovirus B19, Human | 1 | 2011 | 26 | 0.360 |
Why?
|
| Consensus | 3 | 2024 | 565 | 0.360 |
Why?
|
| Parvoviridae Infections | 1 | 2011 | 34 | 0.360 |
Why?
|
| Physician-Patient Relations | 2 | 2013 | 435 | 0.360 |
Why?
|
| Cellulitis | 1 | 2011 | 62 | 0.350 |
Why?
|
| Caregivers | 4 | 2022 | 583 | 0.350 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2013 | 133 | 0.340 |
Why?
|
| Cicatrix | 2 | 2017 | 127 | 0.320 |
Why?
|
| Psoriasis | 2 | 2013 | 52 | 0.320 |
Why?
|
| Male | 42 | 2025 | 65158 | 0.320 |
Why?
|
| Body Image | 1 | 2010 | 39 | 0.320 |
Why?
|
| Administration, Topical | 5 | 2024 | 132 | 0.320 |
Why?
|
| Patient Participation | 1 | 2013 | 244 | 0.320 |
Why?
|
| Medication Adherence | 1 | 2013 | 334 | 0.300 |
Why?
|
| Mood Disorders | 1 | 2010 | 131 | 0.300 |
Why?
|
| Argyria | 1 | 2008 | 1 | 0.280 |
Why?
|
| Silver Sulfadiazine | 1 | 2008 | 9 | 0.280 |
Why?
|
| Communication | 1 | 2013 | 530 | 0.280 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 2008 | 5 | 0.280 |
Why?
|
| Collodion | 1 | 2008 | 8 | 0.280 |
Why?
|
| Child, Preschool | 23 | 2025 | 15047 | 0.280 |
Why?
|
| Female | 37 | 2025 | 71086 | 0.280 |
Why?
|
| Silver | 1 | 2008 | 27 | 0.280 |
Why?
|
| Streptococcus | 1 | 2008 | 63 | 0.270 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2008 | 69 | 0.270 |
Why?
|
| Immunoglobulin G | 2 | 2011 | 810 | 0.260 |
Why?
|
| Bacterial Toxins | 1 | 2008 | 171 | 0.260 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 463 | 0.250 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 1386 | 0.250 |
Why?
|
| Diagnosis, Differential | 7 | 2015 | 1910 | 0.250 |
Why?
|
| Staphylococcus aureus | 2 | 2020 | 485 | 0.240 |
Why?
|
| Skin Care | 2 | 2020 | 14 | 0.240 |
Why?
|
| Adolescent | 25 | 2025 | 20918 | 0.240 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2006 | 72 | 0.240 |
Why?
|
| Nevus | 2 | 2024 | 34 | 0.230 |
Why?
|
| Dermatomycoses | 1 | 2005 | 18 | 0.230 |
Why?
|
| Netherton Syndrome | 1 | 2025 | 2 | 0.230 |
Why?
|
| Opportunistic Infections | 1 | 2005 | 72 | 0.220 |
Why?
|
| Collagen Type VII | 1 | 2025 | 29 | 0.220 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2025 | 125 | 0.220 |
Why?
|
| Pruritus | 2 | 2014 | 50 | 0.220 |
Why?
|
| Quality of Life | 2 | 2025 | 2107 | 0.220 |
Why?
|
| Foot Diseases | 1 | 2004 | 21 | 0.210 |
Why?
|
| Low-Level Light Therapy | 2 | 2021 | 19 | 0.210 |
Why?
|
| Nevus, Sebaceous of Jadassohn | 1 | 2024 | 1 | 0.210 |
Why?
|
| Asthma | 1 | 2013 | 927 | 0.210 |
Why?
|
| Mutation | 10 | 2018 | 6176 | 0.210 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2003 | 18 | 0.210 |
Why?
|
| Hamartoma | 1 | 2004 | 52 | 0.210 |
Why?
|
| Failure to Thrive | 1 | 2024 | 88 | 0.200 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 3411 | 0.200 |
Why?
|
| Virtual Reality | 1 | 2023 | 34 | 0.200 |
Why?
|
| Immunoglobulin A | 1 | 2024 | 210 | 0.200 |
Why?
|
| Skin Diseases, Vascular | 1 | 2022 | 2 | 0.190 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2003 | 147 | 0.190 |
Why?
|
| Telangiectasis | 1 | 2022 | 9 | 0.190 |
Why?
|
| Abnormalities, Multiple | 3 | 2024 | 974 | 0.190 |
Why?
|
| Biological Products | 1 | 2025 | 144 | 0.190 |
Why?
|
| Transition to Adult Care | 1 | 2024 | 134 | 0.180 |
Why?
|
| Treatment Outcome | 9 | 2025 | 12937 | 0.180 |
Why?
|
| Epidermolysis Bullosa, Junctional | 1 | 2021 | 4 | 0.180 |
Why?
|
| Skin Cream | 2 | 2019 | 8 | 0.180 |
Why?
|
| Ointments | 2 | 2019 | 13 | 0.180 |
Why?
|
| Epidermolysis Bullosa Simplex | 1 | 2021 | 6 | 0.180 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2023 | 174 | 0.180 |
Why?
|
| Sturge-Weber Syndrome | 1 | 2021 | 9 | 0.170 |
Why?
|
| Port-Wine Stain | 1 | 2021 | 10 | 0.170 |
Why?
|
| Staphylococcal Infections | 2 | 2020 | 569 | 0.170 |
Why?
|
| Detergents | 1 | 2020 | 21 | 0.160 |
Why?
|
| Self Care | 2 | 2020 | 231 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 5 | 2020 | 2566 | 0.160 |
Why?
|
| Off-Label Use | 1 | 2019 | 26 | 0.150 |
Why?
|
| Wound Healing | 3 | 2017 | 476 | 0.150 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 1168 | 0.150 |
Why?
|
| Triamcinolone Acetonide | 1 | 2019 | 20 | 0.150 |
Why?
|
| Cetirizine | 1 | 2019 | 4 | 0.150 |
Why?
|
| Diphenhydramine | 1 | 2019 | 12 | 0.150 |
Why?
|
| Mucous Membrane | 1 | 2019 | 88 | 0.150 |
Why?
|
| Anxiety | 3 | 2023 | 1003 | 0.150 |
Why?
|
| Ranitidine | 1 | 2019 | 30 | 0.150 |
Why?
|
| Osteomalacia | 2 | 2013 | 7 | 0.150 |
Why?
|
| Iatrogenic Disease | 1 | 2019 | 120 | 0.140 |
Why?
|
| Mevalonate Kinase Deficiency | 1 | 2018 | 1 | 0.140 |
Why?
|
| Emergency Service, Hospital | 2 | 2024 | 1217 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2019 | 576 | 0.140 |
Why?
|
| Connexins | 2 | 2011 | 64 | 0.140 |
Why?
|
| Quality Improvement | 1 | 2024 | 706 | 0.140 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2018 | 79 | 0.140 |
Why?
|
| Primary Health Care | 1 | 2024 | 785 | 0.130 |
Why?
|
| Young Adult | 7 | 2025 | 10092 | 0.130 |
Why?
|
| Isotretinoin | 1 | 2017 | 19 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 506 | 0.120 |
Why?
|
| Physicians, Primary Care | 1 | 2017 | 99 | 0.120 |
Why?
|
| Skin Ulcer | 2 | 2014 | 33 | 0.120 |
Why?
|
| Age Factors | 4 | 2014 | 2870 | 0.120 |
Why?
|
| Surveys and Questionnaires | 6 | 2024 | 4037 | 0.120 |
Why?
|
| Heterozygote | 1 | 2017 | 728 | 0.110 |
Why?
|
| Clinical Competence | 2 | 2024 | 1050 | 0.110 |
Why?
|
| Skin Absorption | 2 | 2019 | 7 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 1809 | 0.100 |
Why?
|
| North America | 3 | 2021 | 256 | 0.100 |
Why?
|
| Hypophosphatemia | 1 | 2013 | 9 | 0.100 |
Why?
|
| Nevus, Pigmented | 1 | 2013 | 30 | 0.100 |
Why?
|
| Dermatitis, Exfoliative | 1 | 2013 | 4 | 0.100 |
Why?
|
| Anal Canal | 1 | 2014 | 86 | 0.100 |
Why?
|
| Education, Medical | 1 | 2017 | 288 | 0.100 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 5277 | 0.100 |
Why?
|
| Growth and Development | 1 | 2013 | 21 | 0.100 |
Why?
|
| Delphi Technique | 2 | 2024 | 262 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 1008 | 0.090 |
Why?
|
| GTP Phosphohydrolases | 1 | 2013 | 159 | 0.090 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 174 | 0.090 |
Why?
|
| Rothmund-Thomson Syndrome | 2 | 2003 | 48 | 0.090 |
Why?
|
| Impetigo | 1 | 2012 | 5 | 0.090 |
Why?
|
| Fibroblast Growth Factors | 1 | 2013 | 169 | 0.090 |
Why?
|
| Disinfectants | 1 | 2012 | 29 | 0.090 |
Why?
|
| Adenosine Triphosphatases | 2 | 2003 | 188 | 0.090 |
Why?
|
| Palatal Neoplasms | 1 | 2011 | 5 | 0.090 |
Why?
|
| Adult | 10 | 2025 | 31666 | 0.090 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2014 | 231 | 0.090 |
Why?
|
| DNA Helicases | 2 | 2003 | 230 | 0.090 |
Why?
|
| Immunoglobulin M | 1 | 2011 | 213 | 0.090 |
Why?
|
| Disease Management | 1 | 2015 | 563 | 0.080 |
Why?
|
| Sex Characteristics | 1 | 2013 | 338 | 0.080 |
Why?
|
| Administration, Cutaneous | 2 | 2008 | 68 | 0.080 |
Why?
|
| Simplexvirus | 1 | 2011 | 100 | 0.080 |
Why?
|
| Sebaceous Glands | 1 | 2010 | 3 | 0.080 |
Why?
|
| Propionibacterium acnes | 1 | 2010 | 13 | 0.080 |
Why?
|
| Prognosis | 2 | 2019 | 4951 | 0.080 |
Why?
|
| Herpes Simplex | 1 | 2011 | 56 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 3 | 2024 | 1305 | 0.080 |
Why?
|
| Keratosis | 1 | 2010 | 18 | 0.080 |
Why?
|
| Retinoids | 3 | 2020 | 29 | 0.080 |
Why?
|
| Mosaicism | 2 | 2009 | 243 | 0.080 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2010 | 76 | 0.080 |
Why?
|
| Liver | 1 | 2017 | 1795 | 0.080 |
Why?
|
| Hypopigmentation | 1 | 2009 | 11 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2009 | 47 | 0.080 |
Why?
|
| Puberty, Precocious | 1 | 2009 | 29 | 0.070 |
Why?
|
| Retrospective Studies | 6 | 2025 | 17648 | 0.070 |
Why?
|
| Bandages | 2 | 2019 | 55 | 0.070 |
Why?
|
| Canada | 2 | 2020 | 327 | 0.070 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2012 | 391 | 0.070 |
Why?
|
| Aneuploidy | 1 | 2009 | 141 | 0.070 |
Why?
|
| Risk Assessment | 5 | 2019 | 3693 | 0.070 |
Why?
|
| Biopsy | 1 | 2011 | 1249 | 0.070 |
Why?
|
| Aminoquinolines | 1 | 2008 | 36 | 0.070 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2011 | 268 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2008 | 741 | 0.070 |
Why?
|
| Ectodermal Dysplasia 1, Anhidrotic | 1 | 2007 | 1 | 0.070 |
Why?
|
| Capillaries | 1 | 2007 | 67 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2010 | 469 | 0.060 |
Why?
|
| Hearing Loss, Sensorineural | 2 | 2011 | 155 | 0.060 |
Why?
|
| Fetal Diseases | 1 | 2011 | 460 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2024 | 1450 | 0.060 |
Why?
|
| Diseases in Twins | 1 | 2007 | 90 | 0.060 |
Why?
|
| Incontinentia Pigmenti | 1 | 2006 | 16 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 2985 | 0.060 |
Why?
|
| Etanercept | 1 | 2006 | 44 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2008 | 1624 | 0.060 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2011 | 500 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2013 | 1612 | 0.060 |
Why?
|
| Angiomatosis | 1 | 2005 | 6 | 0.060 |
Why?
|
| Biopsy, Needle | 3 | 2019 | 216 | 0.060 |
Why?
|
| Prevalence | 3 | 2021 | 2692 | 0.060 |
Why?
|
| Parents | 1 | 2013 | 1109 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 758 | 0.060 |
Why?
|
| Antibodies, Viral | 1 | 2011 | 1169 | 0.060 |
Why?
|
| Sex Distribution | 2 | 2019 | 322 | 0.060 |
Why?
|
| Streptococcal Infections | 1 | 2008 | 248 | 0.060 |
Why?
|
| Photosensitivity Disorders | 1 | 2004 | 11 | 0.060 |
Why?
|
| DNA | 2 | 2008 | 1442 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 1487 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2020 | 1223 | 0.050 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2004 | 44 | 0.050 |
Why?
|
| Age Distribution | 2 | 2019 | 429 | 0.050 |
Why?
|
| Trichotillomania | 1 | 2004 | 32 | 0.050 |
Why?
|
| Single-Blind Method | 2 | 2019 | 241 | 0.050 |
Why?
|
| Recurrence | 1 | 2008 | 1478 | 0.050 |
Why?
|
| Developmental Disabilities | 1 | 2009 | 760 | 0.050 |
Why?
|
| Triazoles | 1 | 2004 | 143 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2005 | 221 | 0.050 |
Why?
|
| Amebicides | 1 | 2003 | 1 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2019 | 1521 | 0.050 |
Why?
|
| Middle Aged | 5 | 2025 | 28839 | 0.050 |
Why?
|
| Acanthamoeba | 1 | 2003 | 9 | 0.050 |
Why?
|
| Collagen Diseases | 1 | 2003 | 4 | 0.050 |
Why?
|
| Amebiasis | 1 | 2003 | 11 | 0.050 |
Why?
|
| Livedo Reticularis | 1 | 2022 | 1 | 0.050 |
Why?
|
| Hair Removal | 1 | 2003 | 8 | 0.050 |
Why?
|
| Disease Progression | 3 | 2019 | 2205 | 0.050 |
Why?
|
| Observer Variation | 1 | 2024 | 319 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2019 | 1610 | 0.050 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2003 | 132 | 0.050 |
Why?
|
| Gastrostomy | 1 | 2022 | 88 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2019 | 6485 | 0.040 |
Why?
|
| Patient Transfer | 1 | 2022 | 110 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 340 | 0.040 |
Why?
|
| Texas | 2 | 2024 | 3614 | 0.040 |
Why?
|
| Pain Management | 1 | 2023 | 199 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2004 | 443 | 0.040 |
Why?
|
| Lasers, Dye | 1 | 2021 | 2 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2021 | 420 | 0.040 |
Why?
|
| Mupirocin | 1 | 2020 | 20 | 0.040 |
Why?
|
| Vitamin D Deficiency | 1 | 2002 | 85 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 1313 | 0.040 |
Why?
|
| Osteoporosis | 1 | 2002 | 134 | 0.040 |
Why?
|
| Pain | 1 | 2023 | 439 | 0.040 |
Why?
|
| United States | 3 | 2024 | 11794 | 0.040 |
Why?
|
| Enteral Nutrition | 1 | 2022 | 281 | 0.040 |
Why?
|
| Osteosarcoma | 1 | 2003 | 265 | 0.040 |
Why?
|
| Cosmetics | 1 | 2020 | 12 | 0.040 |
Why?
|
| Cholestasis | 1 | 2002 | 165 | 0.040 |
Why?
|
| Puberty | 2 | 2010 | 104 | 0.040 |
Why?
|
| Pediatrics | 1 | 2009 | 1230 | 0.040 |
Why?
|
| Patient Care Management | 1 | 2019 | 61 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2019 | 22 | 0.040 |
Why?
|
| Genotype | 1 | 2025 | 2655 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2003 | 929 | 0.040 |
Why?
|
| Drug Approval | 1 | 2019 | 45 | 0.040 |
Why?
|
| Risk Factors | 3 | 2009 | 10952 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 714 | 0.040 |
Why?
|
| Immunoglobulin D | 1 | 2018 | 6 | 0.040 |
Why?
|
| Connexin 26 | 2 | 2011 | 13 | 0.040 |
Why?
|
| Bone Neoplasms | 1 | 2003 | 444 | 0.040 |
Why?
|
| Incidence | 3 | 2019 | 3344 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2022 | 566 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 313 | 0.030 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2018 | 55 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 3834 | 0.030 |
Why?
|
| Health Personnel | 1 | 2022 | 549 | 0.030 |
Why?
|
| Fear | 1 | 2019 | 198 | 0.030 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2017 | 37 | 0.030 |
Why?
|
| Fatal Outcome | 2 | 2011 | 364 | 0.030 |
Why?
|
| Antirheumatic Agents | 1 | 2018 | 118 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 395 | 0.030 |
Why?
|
| Syndrome | 2 | 2009 | 1166 | 0.030 |
Why?
|
| Oils | 1 | 2014 | 5 | 0.030 |
Why?
|
| Hospitalization | 1 | 2024 | 1939 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2013 | 1745 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2019 | 5120 | 0.020 |
Why?
|
| Nails | 1 | 2013 | 21 | 0.020 |
Why?
|
| Scalp | 1 | 2013 | 58 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 909 | 0.020 |
Why?
|
| RecQ Helicases | 2 | 2003 | 63 | 0.020 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2010 | 18 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 1685 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2011 | 433 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 644 | 0.020 |
Why?
|
| Facial Neoplasms | 1 | 2009 | 23 | 0.020 |
Why?
|
| Sternum | 1 | 2009 | 50 | 0.020 |
Why?
|
| Eye | 1 | 2011 | 227 | 0.020 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2009 | 53 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2011 | 286 | 0.020 |
Why?
|
| Exome | 1 | 2013 | 1076 | 0.020 |
Why?
|
| Aortic Coarctation | 1 | 2009 | 98 | 0.020 |
Why?
|
| Interferon Inducers | 1 | 2008 | 6 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2010 | 705 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2008 | 175 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 310 | 0.020 |
Why?
|
| Embryonic Development | 1 | 2009 | 225 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 6273 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2008 | 320 | 0.020 |
Why?
|
| Twins, Dizygotic | 1 | 2007 | 46 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2017 | 1213 | 0.020 |
Why?
|
| Femoral Artery | 1 | 2007 | 135 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 1258 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2007 | 165 | 0.020 |
Why?
|
| Leg | 1 | 2007 | 123 | 0.020 |
Why?
|
| Tooth Abnormalities | 1 | 2006 | 13 | 0.020 |
Why?
|
| Karyotyping | 1 | 2006 | 314 | 0.010 |
Why?
|
| Eosinophils | 1 | 2006 | 126 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 237 | 0.010 |
Why?
|
| Radiography | 1 | 2007 | 760 | 0.010 |
Why?
|
| Craniofacial Abnormalities | 1 | 2007 | 255 | 0.010 |
Why?
|
| Voriconazole | 1 | 2004 | 30 | 0.010 |
Why?
|
| Nervous System Malformations | 1 | 2006 | 133 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2004 | 18 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2005 | 110 | 0.010 |
Why?
|
| Gels | 1 | 2004 | 70 | 0.010 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2004 | 70 | 0.010 |
Why?
|
| Sex Factors | 1 | 2008 | 1345 | 0.010 |
Why?
|
| Pedigree | 1 | 2007 | 1710 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2005 | 418 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 2003 | 208 | 0.010 |
Why?
|
| Ear | 1 | 2003 | 27 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2005 | 350 | 0.010 |
Why?
|
| Inflammation | 1 | 2010 | 1490 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 436 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2002 | 120 | 0.010 |
Why?
|
| Antifungal Agents | 1 | 2004 | 298 | 0.010 |
Why?
|
| Registries | 1 | 2009 | 1599 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 2002 | 83 | 0.010 |
Why?
|
| Introns | 1 | 2002 | 287 | 0.010 |
Why?
|
| RNA Splicing | 1 | 2002 | 234 | 0.010 |
Why?
|
| Transfection | 1 | 2002 | 960 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 1236 | 0.010 |
Why?
|
| Alleles | 1 | 2003 | 1708 | 0.010 |
Why?
|
| Pregnancy | 1 | 2011 | 7572 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 2782 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2002 | 1233 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 2009 | 1894 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 3614 | 0.010 |
Why?
|
| Brain | 1 | 2009 | 3237 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 2143 | 0.010 |
Why?
|
| Aged | 1 | 2014 | 21238 | 0.010 |
Why?
|
| Biomarkers | 1 | 2005 | 3403 | 0.010 |
Why?
|
| Animals | 2 | 2003 | 34335 | 0.010 |
Why?
|
| Mice | 1 | 2002 | 18470 | 0.000 |
Why?
|